These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 20578891)

  • 1. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
    Hou P; Liu D; Shan Y; Hu S; Studeman K; Condouris S; Wang Y; Trink A; El-Naggar AK; Tallini G; Vasko V; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1161-70. PubMed ID: 17317825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
    Wang Y; Hou P; Yu H; Wang W; Ji M; Zhao S; Yan S; Sun X; Liu D; Shi B; Zhu G; Condouris S; Xing M
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2387-90. PubMed ID: 17426084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
    Hou P; Ji M; Xing M
    Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer.
    Liu D; Yang C; Bojdani E; Murugan AK; Xing M
    J Natl Cancer Inst; 2013 Nov; 105(21):1617-27. PubMed ID: 24136889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
    Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
    J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
    Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
    Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
    Brzezianska E; Pastuszak-Lewandoska D
    Front Biosci (Landmark Ed); 2011 Jan; 16(2):422-39. PubMed ID: 21196179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic alterations in MAPK and PI3K/Akt signaling pathways and the generation, progression, diagnosis and therapy of thyroid cancer].
    Liu B; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Dec; 29(6):1221-5. PubMed ID: 23469561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
    Sáez JM
    Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
    Wu G; Mambo E; Guo Z; Hu S; Huang X; Gollin SM; Trink B; Ladenson PW; Sidransky D; Xing M
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4688-93. PubMed ID: 15928251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.
    Liu R; Liu D; Trink E; Bojdani E; Ning G; Xing M
    J Clin Endocrinol Metab; 2011 Apr; 96(4):E577-85. PubMed ID: 21289267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
    Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intracellular signaling mechanisms in thyroid cancer].
    Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
    Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
    Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S
    Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of the PIK3CA gene in anaplastic thyroid cancer.
    García-Rostán G; Costa AM; Pereira-Castro I; Salvatore G; Hernandez R; Hermsem MJ; Herrero A; Fusco A; Cameselle-Teijeiro J; Santoro M
    Cancer Res; 2005 Nov; 65(22):10199-207. PubMed ID: 16288007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.